Behzad Aghazadeh - Net Worth and Insider Trading

Behzad Aghazadeh Net Worth

The estimated net worth of Behzad Aghazadeh is at least $1.4 Billion dollars as of 2023-09-24. Behzad Aghazadeh is the See Remarks of Immunomedics Inc and owns about 16,064,461 shares of Immunomedics Inc (IMMU) stock worth over $1.4 Billion. Details can be seen in Behzad Aghazadeh's Latest Holdings Summary section.

Transaction Summary of Behzad Aghazadeh


Behzad Aghazadeh Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Behzad Aghazadeh owns 4 companies in total, including CymaBay Therapeutics Inc (CBAY) , Immunomedics Inc (IMMU) , and Mirati Therapeutics Inc (MRTX) among others .

Click here to see the complete history of Behzad Aghazadeh’s form 4 insider trades.

Insider Ownership Summary of Behzad Aghazadeh

Ticker Comapny Transaction Date Type of Owner
CBAY CymaBay Therapeutics Inc 2020-08-03 10 percent owner
IMMU Immunomedics Inc 2020-06-18 director & 10 percent owner & other: See Remarks
MRTX Mirati Therapeutics Inc 2017-09-15 10 percent owner
AADI Aadi Bioscience Inc 2021-08-26 director & other: See Remarks

Behzad Aghazadeh Latest Holdings Summary

Behzad Aghazadeh currently owns a total of 1 stock. Behzad Aghazadeh owns 16,064,461 shares of Immunomedics Inc (IMMU) as of November 15, 2017, with a value of $1.4 Billion.

Latest Holdings of Behzad Aghazadeh

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
IMMU Immunomedics Inc 2017-11-15 16,064,461 87.86 1,411,423,543

Holding Weightings of Behzad Aghazadeh

Behzad Aghazadeh Form 4 Trading Tracker

According to the SEC Form 4 filings, Behzad Aghazadeh has made a total of 0 transactions in Immunomedics Inc (IMMU) over the past 5 years. The most-recent trade in Immunomedics Inc is the acquisition of 1,325,000 shares on November 15, 2017, which cost Behzad Aghazadeh around $14 Million.

Insider Trading History of Behzad Aghazadeh

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Behzad Aghazadeh Trading Performance

GuruFocus tracks the stock performance after each of Behzad Aghazadeh's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Behzad Aghazadeh is 44.95%. GuruFocus also compares Behzad Aghazadeh's trading performance to market benchmark return within the same time period. The performance of stocks bought by Behzad Aghazadeh within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Behzad Aghazadeh's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Behzad Aghazadeh

Average Relative Return


Average relative return per transaction

Outperforming Transactions


1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Relative Return(%) 10.18 44.95 69.19 70.36 25.71
Relative Return to S&P 500(%) 5.84 38.45 63.46 63.9 15.4

Behzad Aghazadeh Ownership Network

Ownership Network List of Behzad Aghazadeh

No Data

Ownership Network Relation of Behzad Aghazadeh

Behzad Aghazadeh Owned Company Details

What does CymaBay Therapeutics Inc do?

CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with liver and other chronic diseases with high unmet medical need. Its product in pipeline includes two clinical stage product candidates: seladelpar (a PPARd agonist) and MBX-2982 (a GPR119 agonist).

Who are the key executives at CymaBay Therapeutics Inc?

Behzad Aghazadeh is the 10 percent owner of CymaBay Therapeutics Inc. Other key executives at CymaBay Therapeutics Inc include Chief Financial Officer Harish Shantharam , Vice President & Finance Daniel Menold , and Chief Scientific Officer Charles Mcwherter .

CymaBay Therapeutics Inc (CBAY) Insider Trades Summary

Over the past 18 months, Behzad Aghazadeh made no insider transaction in CymaBay Therapeutics Inc (CBAY). Other recent insider transactions involving CymaBay Therapeutics Inc (CBAY) include a net sale of 108,739 shares made by Charles Mcwherter , a net sale of 73,000 shares made by Paul T Quinlan , and a net sale of 120,100 shares made by Dennis D Kim .

In summary, during the past 3 months, insiders sold 154,186 shares of CymaBay Therapeutics Inc (CBAY) in total and bought 0 shares, with a net sale of 154,186 shares. During the past 18 months, 322,784 shares of CymaBay Therapeutics Inc (CBAY) were sold and 51,301 shares were bought by its insiders, resulting in a net sale of 271,483 shares.

CymaBay Therapeutics Inc (CBAY)'s detailed insider trading history can be found in Insider Trading Tracker table.


CymaBay Therapeutics Inc Insider Transactions

No Available Data

Behzad Aghazadeh Mailing Address

Above is the net worth, insider trading, and ownership report for Behzad Aghazadeh. You might contact Behzad Aghazadeh via mailing address: C/o Avoro Capital Advisors Llc, 110 Greene Street, Suite 800, New York Ny 10012.

Discussions on Behzad Aghazadeh

No discussions yet.